Publicaciones (118) Publicaciones de MATILDE MERINO SANJUAN

2024

  1. Bioequivalence risk assessment of oral formulations containing racemic ibuprofen through a chiral physiologically based pharmacokinetic model of ibuprofen enantiomers

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 199

  2. Phys-DAT: A physiologically-based pharmacokinetic model for unraveling the dissolution, transit and absorption processes using PhysPK®

    Computer Methods and Programs in Biomedicine, Vol. 243

2023

  1. Application of population physiologically based pharmacokinetic modelling to optimize target expression and clearance mechanisms of therapeutic monoclonal antibodies

    British Journal of Clinical Pharmacology, Vol. 89, Núm. 9, pp. 2691-2702

  2. Commonly used methods for dissolution profile comparison

    Time-Proof Perspectives on Bioequivalence (Nova Science Publishers, Inc.), pp. 297-322

  3. Desarrollo y validación de un modelo farmacocinético fisiológico para las formas ácidas y lactonizadas de atorvastatina y sus dos metabolitos

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  4. Evolución de parámetros representativos de la estructura interna de diclofenaco emulgel 1% durante el periodo de conservación

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  5. Farmacometría aplicada a la personalización de tratamientos

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

2022

  1. A physiologically based pharmacokinetic model for open acid and lactone forms of atorvastatin and metabolites to assess the drug-gene interaction with SLCO1B1 polymorphisms

    Biomedicine and Pharmacotherapy, Vol. 156

  2. Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis

    Pharmaceutics, Vol. 14, Núm. 3

  3. Pharmacometric characterization of entero-hepatic circulation processes of orally administered formulations of amiodarone under complex binding kinetics

    European Journal of Pharmaceutical Sciences, Vol. 174

  4. Population Pharmacokinetic/Pharmacodynamic Modelling of Daptomycin for Schedule Optimization in Patients with Renal Impairment

    Pharmaceutics, Vol. 14, Núm. 10

  5. Quantitative assessment of the exposure–efficacy relationship of glucocerebrosidase using Markovian elements in Gaucher patients treated with enzyme replacement therapy

    British Journal of Clinical Pharmacology, Vol. 88, Núm. 6, pp. 2727-2737

2021

  1. Current evidence, challenges, and opportunities of physiologically based pharmacokinetic models of atorvastatin for decision making

    Pharmaceutics, Vol. 13, Núm. 5

  2. Estimators and Confidence Intervals of f_2 Using Bootstrap Methodology for the Comparison of Dissolution Profiles

    RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 54-56

  3. Estimators and confidence intervals of f2 using bootstrap methodology for the comparison of dissolution profiles

    Computer Methods and Programs in Biomedicine, Vol. 212

  4. Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing recommendations

    British Journal of Clinical Pharmacology, Vol. 87, Núm. 3, pp. 905-915

  5. Farmacoterapia personalizada en oncología: Aplicación de criterios farmacocinéticos-farmacodinámicos

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 45, Núm. 7, pp. 45-55

  6. In vitro skin penetration of bronidox, bronopol and formaldehyde from cosmetics

    Regulatory Toxicology and Pharmacology, Vol. 122

  7. Physico-Chemical Stability of Admixtures of Vinflunine Used in Clinical Practice

    Journal of Pharmaceutical Sciences, Vol. 110, Núm. 7, pp. 2687-2693

  8. Variabilidad en el perfil de liberación de diclofenaco, formulado como emulgel 1 %, durante su periodo de validez

    RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 195-197